Biotech blue-chip Gilead Sciences (NASDAQ:GILD) has been a Fool favorite for quite some time, thanks in large part to the huge success of its best-selling Hepatitis C treatments Sovaldi and Harvoni. While we certainly have been impressed with the enormous growth that has come from these drugs, we Fools think that there are plenty of other reasons that investors should consider adding Gilead to their portfolios.
Hey, check out all the research scientist jobs. Post your resume today!
